Expert Analysis

Advances in HBV Treatment: 2007

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Advances in HBV Treatment: 2007

Faculty:
Adrian M. Di Bisceglie, MD, FACP Geoffrey M. Dusheiko, MD, FCP(SA), FRCP Daniel Shouval, MD

CME CREDIT INFORMATION

Release Date: 06/27/07

Expiration Date: 06/26/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.3 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount clinical data on long-term therapy for the treatment of chronic hepatitis B
Summarize data regarding management strategies for patients with hepatitis B virus treatment–related resistance
Discuss the use of noninvasive methods and models for assessing stage and rate of progression of liver disease

Topics covered include:

Natural History of Untreated Hepatitis B e Antigen–Positive Chronic Hepatitis B Infection
Presence of Histologic Damage in HBV-Infected Patients With ALT < 2 x Upper Limit of Normal
Transient Elastography for the Detection of Fibrosis in Chronically Infected HBV Patients
Predictive Modeling of Fibrosis
Entecavir vs Adefovir Treatment in HBeAg-Positive Chronic Hepatitis B Patients
HBV-Resistant Mutants With Long-term Lamivudine
Rates of Entecavir Resistance at Year 4 in Nucleoside-Naive and Lamivudine-Refractory Patients
Impact of Lamivudine With or Without Adefovir Treatment on Esophageal Varices
Peginterferon alfa-2a Treatment in Patients With HBeAg-Negative Chronic Hepatitis B
Durability Substudy of the GLOBE Trial: Telbivudine vs Lamivudine in HBeAg-Positive Patients
Switching From Lamivudine to Telbivudine
Is it Beneficial to Overlap When Switching From Nonsuppressive Lamivudine or Telbivudine to Adefovir?

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.